Thoratec Corporation

Skip to content

Ongoing Clinical Trials ()

Explore ongoing and upcoming clinical investigations of our mechanical circulatory support devices for advanced heart failure patients. You can review study objectives, referral indicators, and the latest results of our current clinical trials.

Thoratec is committed to advancing the field of MCS with research into new technologies and therapies in order to deliver on the promise of providing the most effective, advanced treatment options for patients suffering from advanced heart failure.

PREVENT Clinical Study


The PREVENtion of HeartMate II® Pump Thrombosis Through Clinical Management (PREVENT) Study is a prospective, multi-center, non-randomized study (U.S.) that is designed to:

  1. Assess the incidence of HeartMate II pump thrombosis in the current era when recommended practice for clinical management are adopted, and
  2. Identify the risk facts associated with pump thrombosis events.

The recommended practices in the study are focused on implantation technique, anticoagulation regimen, pump speed and blood pressure management.

PREVENT is currently enrolling. The study will enroll up to 300 HeartMate II patients, and will follow them for six months. For more information, please visit the ClinicalTrials.gov website here.


Clinical Outcomes

Review clinical outcome data and results from completed trials.

View Clinical Outcomes

Text Size: A A A

See usage guidelines, research articles, and publications for Thoratec products.

Explore Resource Library